Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
5.7
3.9
Journals
JCM
Special Issues
Advances in the Treatment of Thyroid Cancer
share announcement

Advances in the Treatment of Thyroid Cancer

A special issue of Journal of Clinical Medicine (ISSN 2077-0383). This special issue belongs to the section "Oncology".

Deadline for manuscript submissions: closed (30 April 2023) | Viewed by 6958

Special Issue Editors

Prof. Dr. Wei Cai

E-Mail Website
Guest Editor
Department of General Surgery, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China
Interests: clinical staging and surgical strategy of differentiated thyroid carcinoma; drainage and mechanism of lymph nodemetastasis in thyroid carcinoma; new techniques for differentiating benign and malignant thyroid tumors
Prof. Dr. Weihua Qiu

E-Mail Website
Guest Editor
Department of General Surgery, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China
Interests: clinical monitoring and surgical strategy of differentiated thyroid carcinoma; drainage and mechanism of lymph node metastasis in thyroid carcinoma; targeted therapy strategy for poorly differentiated/anaplastic thyroid carcinoma

Special Issue Information

Dear Colleagues,

Thyroid cancer is the ninth most common cancer worldwide, with 567,000 new cases every year. Although the incidence of thyroid cancer has not increased significantly compared to 2018, thyroid-cancer-related mortality has risen from 3.8% to 4.2%. Therefore, there is an urgent need for recent research progress into the improvement of diagnostics and for the implementation of new treatment methods. The aim of this Special Issue is to present new insights and research progress in the clinical management of thyroid cancer. We would be pleased to receive interesting articles on different aspects of thyroid cancer. Both clinical and experimental studies are welcome. We hope to provide readers of our Special Issue with a broad understanding of these topics.

Professor Dr. Wei Cai
Professor Dr. Weihua Qiu
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Clinical Medicine is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • surgical strategy
  • differentiated thyroid carcinoma (DTC)
  • anaplastic thyroid carcinoma (ATC)
  • lymph node metastasis
  • targeted therapy

Published Papers (4 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Editorial

Jump to: Research

6 pages, 213 KiB  
Editorial
Editorial: Apatinib and Anlotinib in the Treatment of Radioactive Iodine Refractory and Highly Invasive Thyroid Carcinoma
by Wenqing Jia, Zhuoran Liu, Ling Zhan, Qiwu Zhao, Weihua Qiu and Jie Kuang
J. Clin. Med. 2022, 11(21), 6380; https://doi.org/10.3390/jcm11216380 - 28 Oct 2022
Viewed by 1122
Abstract
Thyroid cancer (TC) is the most prevalent endocrine malignancy, with a rising incidence in the past decade [...] Full article
(This article belongs to the Special Issue Advances in the Treatment of Thyroid Cancer)

Research

Jump to: Editorial

13 pages, 1062 KiB  
Article
Outcomes of Surgical Treatment for Graves’ Disease: A Single-Center Experience of 216 Cases
by Hanxing Sun, Hui Tong, Xiaohui Shen, Haoji Gao, Jie Kuang, Xi Chen, Qinyu Li, Weihua Qiu, Zhuoran Liu and Jiqi Yan
J. Clin. Med. 2023, 12(4), 1308; https://doi.org/10.3390/jcm12041308 - 7 Feb 2023
Cited by 2 | Viewed by 1951
Abstract
Background: The role of surgery in the treatment of Graves’ disease (GD) needs to be revisited. The aims of the present retrospective study were to evaluate the outcomes of the current surgical strategy as a definitive treatment of GD at our center and [...] Read more.
Background: The role of surgery in the treatment of Graves’ disease (GD) needs to be revisited. The aims of the present retrospective study were to evaluate the outcomes of the current surgical strategy as a definitive treatment of GD at our center and to explore the clinical association between GD and thyroid cancer. Methods: A patient cohort of 216 cases from 2013 to 2020 was involved in this retrospective study. The data of the clinical characteristics and follow-up results were collected and analyzed. Results: There were 182 female and 34 male patients. The mean age was 43.9 ± 15.0 years old. The mean duration of GD reached 72.2 ± 92.7 months. Of the 216 cases, 211 had been treated with antithyroid drugs (ATDs) and hyperthyroidism had been completely controlled in 198 cases. A total (75%) or near-total (23.6%) thyroidectomy was performed. Intraoperative neural monitoring (IONM) was applied to 37 patients. The failure of ATD therapy (52.3%) was the most common surgical indication, followed by suspicion of a malignant nodule (45.8%). A total of 24 (11.1%) patients had hoarseness after the operation and 15 (6.9%) patients had transient vocal cord paralysis; 3 (1.4%) had this problem permanently. No bilateral RLN paralysis occurred. A total of 45 patients had hypoparathyroidism and 42 of them recovered within 6 months. Sex showed a correlation with hypoparathyroidism through a univariate analysis. A total of 2 (0.9%) patients underwent a reoperation because of hematomas. A total of 104 (48.1%) cases were diagnosed as thyroid cancer. In most cases (72.1%), the malignant nodules were microcarcinomas. A total of 38 patients had a central compartment node metastasis. A lateral lymph node metastasis occurred in 10 patients. Thyroid carcinomas were incidentally discovered in the specimens of 7 cases. The patients with concomitant thyroid cancer had a significant difference in body mass index, duration of GD, gland size, thyrotropin receptor antibodies and nodule(s) detected. Conclusion: Surgical treatments for GD were effective, with a relatively low incidence of complications at this high-volume center. Concomitant thyroid cancer is one of the most important surgical indications for GD patients. Careful ultrasonic screening is necessary to exclude the presence of malignancies and to determine the therapeutic plan. Full article
(This article belongs to the Special Issue Advances in the Treatment of Thyroid Cancer)
►▼ Show Figures

Figure 1

12 pages, 4382 KiB  
Article
Prognostic Values of METTL3 and Its Roles in Tumor Immune Microenvironment in Pan-Cancer
by Yang Guo, Yu Heng, Hui Chen, Qiang Huang, Chunping Wu, Lei Tao and Liang Zhou
J. Clin. Med. 2023, 12(1), 155; https://doi.org/10.3390/jcm12010155 - 25 Dec 2022
Cited by 1 | Viewed by 1989
Abstract
Background: N6-methyladenosine (m6A) is among the most prevalent RNA modifications regulating RNA metabolism. The roles of methyltransferase-like 3 (METTL3), a core catalytic subunit, in various cancers remain unclear. Methods: The expression levels of METTL3 in pan-cancer were profiled and their prognostic [...] Read more.
Background: N6-methyladenosine (m6A) is among the most prevalent RNA modifications regulating RNA metabolism. The roles of methyltransferase-like 3 (METTL3), a core catalytic subunit, in various cancers remain unclear. Methods: The expression levels of METTL3 in pan-cancer were profiled and their prognostic values were examined. We assessed the relationships between METTL3 expression levels and tumor immune infiltration levels, immune checkpoint gene expression, immune neoantigens, tumor mutation burden, microsatellite instability, and DNA mismatch repair gene expression. Furthermore, a protein–protein interaction network was drawn, and gene set enrichment analysis was conducted to explore the functions of METTL3. Results: METTL3 expression levels were elevated in most cancers, with high expression associated with poorer overall and disease-free survival. METTL3 levels were significantly related to immune cell infiltration, tumor mutation burden, microsatellite instability, mismatch repair genes, and immune checkpoint gene levels. METTL3 was enriched in pathways related to RNA modification and metabolism and correlated with epithelial–mesenchymal transition. Conclusions: METTL3 serves as an oncogene in most cancer types and shows potential as a prognostic biomarker. Additionally, our comprehensive pan-cancer analysis suggested that METTL3 is involved in regulating the tumor immune microenvironments and epithelial–mesenchymal transition via modulating RNA modification and metabolism, making it a potential therapeutic target. Full article
(This article belongs to the Special Issue Advances in the Treatment of Thyroid Cancer)
►▼ Show Figures

Figure 1

16 pages, 1731 KiB  
Article
Lateral Involvement in Different Sized Papillary Thyroid Carcinomas Patients with Central Lymph Node Metastasis: A Multi-Center Analysis
by Yu Heng, Zheyu Yang, Pengyu Cao, Xi Cheng and Lei Tao
J. Clin. Med. 2022, 11(17), 4975; https://doi.org/10.3390/jcm11174975 - 24 Aug 2022
Cited by 2 | Viewed by 1297
Abstract
Objective: To quantitatively predict the probability of lateral lymph node metastasis (LLNM) for papillary thyroid carcinomas (PTC) patients with central lymph node metastasis (CLNM) in order to guide postoperative adjuvant treatment. Methods: Five hundred and three PTC patients with CLNM from three medical [...] Read more.
Objective: To quantitatively predict the probability of lateral lymph node metastasis (LLNM) for papillary thyroid carcinomas (PTC) patients with central lymph node metastasis (CLNM) in order to guide postoperative adjuvant treatment. Methods: Five hundred and three PTC patients with CLNM from three medical centers were retrospectively analyzed. Results: The LLNM rate for all patients was 23.9% (120 in 503), with 15.5% (45 in 291) and 35.4% (75 in 212) for patients with papillary thyroid microcarcinoma (PTMC) and large papillary thyroid carcinoma (LPTC), respectively. Patients with no fewer than five positive central lymph nodes (CLN) exhibited a higher risk of LLNM. For patients with fewer than five positive CLN, a maximum diameter of positive CLN > 0.5 cm and the presence of ipsilateral nodular goiter were identified as independent risk factors of LLNM for papillary thyroid microcarcinoma (PTMC) patients. The independent risk factors of LLNM for large papillary thyroid carcinoma (LPTC) patients included a tumor located in the upper portion of thyroid, maximum tumor diameter ≥ 2.0 cm, maximum diameter of positive CLN > 0.5 cm, and the presence of thyroid capsular invasion. Predictive nomograms were established based on these risk factors for PTMC and LPTC patients, respectively. The accuracy and validity of our newly built models were verified by C-index and calibration curves. PTMC and LPTC patients with fewer than five positive CLN were each stratified into three subgroups based on their nomogram risk scores, and a detailed risk stratification flow chart was established for a more accurate evaluation of LLNM risk in PTC patients. Conclusions: A detailed stratification flow chart for PTC patients with CLNM to quantitatively assess LLNM risk was established, which may aid in clinical decision-making for those patients. Full article
(This article belongs to the Special Issue Advances in the Treatment of Thyroid Cancer)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-4
Back to TopTop